Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034095 | 0.90 | KIF11 (0.75) | KIF11KCNH2 | |
| SCHEMBL4034097 | 0.90 | KIF11 (0.75) | KIF11KCNH2 | |
| SCHEMBL4061035 | 0.86 | KIF11 (0.80) | KIF11KCNH2 | |
| SCHEMBL4066081 | 0.83 | KIF11 (0.66) | KIF11KCNH2 | |
| SCHEMBL4058422 | 0.82 | KIF11 (0.65) | KIF11KCNH2 | |
| SCHEMBL4062122 | 0.82 | KIF11 (0.80) | KIF11KCNH2 | |
| SCHEMBL27626778 | 0.80 | KIF11 (0.56) | KIF11KCNH2 | |
| SCHEMBL14095709 | 0.79 | KIF11 (0.46) | KIF11KCNH2 | |
| SCHEMBL14095706 | 0.79 | KIF11 (0.46) | KIF11KCNH2 | |
| SCHEMBL27607777 | 0.79 | KIF11 (0.57) | KIF11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515724-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1515724-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1636182-A4 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7348440-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348440-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348440-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7329762-B2 | Prodrugs of mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329762-B2 | Prodrugs of mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329762-B2 | Prodrugs of mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20060135594-A1 | Prodrugs of mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-06-22 | — | — | US | disclosed |
| US-20060105997-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
| EP-1636182-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1515724-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1515724-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004111193-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004087050-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2003105855-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135594-A1 | Prodrugs of mitotic kinesin inhibitors | KIF2C, KIF5B, KIFC1 | KIF11 11/4885KCNH2 2099/4885 |
| US-20060105997-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | KIF11 8/4885KCNH2 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.